The impact of morphine treatment on bladder cancer cell proliferation and apoptosis: in vitro studies
Summary. Aim: The aim of this study was to determine the effect of morphine on bladder cancer cell proliferation and apoptosis in vitro. Materials and Methods: MTT assay was used to measure percentage growth of RT-112 human bladder cancer cells after 72 hours of morphine/morphine + naloxone treatment. Expression of µ-opioid receptors was assessed by Western blot and finally, apoptotic assay with CellEvent Caspase-3/7 Green Detection Reagent was carried out using confocal microscopy. Results: The MTT assays showed that morphine increased RT-112 cell growth. Naloxone inhibited this growth enhancing effect. Western blot analysis regarding µ-opioid receptor expression in RT-112 cells remains inconclusive. Morphine was also found to decrease the rate of apoptosis of RT-112 cells, an effect which naloxone inhibited. Conclusions: This study provides evidence that morphine, at clinically relevant doses, causes RT-112 bladder cancer cell proliferation, possibly opioid receptor mediated and at least some of this effect might be due to decreased apoptosis. Clinically, this suggests that in patients with bladder cancer, managing pain with morphine might have detrimental consequences on patient outcomes and alternative pain relief should be considered if possible.
Submitted: April 27, 2018.
*Correspondence: E-mail: email@example.com
Abbreviations used: MTT — methylthiazolyldiphenyl-tetrazolium bromide.
Bladder cancer is the ninth most common cancer worldwide, encompassing several types of cancer which arise from the urothelium. According to GLOBOCAN estimates, around 430,000 new bladder cancer cases and 165,000 bladder cancer deaths occurred globally in 2012 . Morphine plays a role in the management of bladder cancer, specifically, in peri-operative analgesia during tumour resections and radical cystectomy for more advanced disease. However, in recent years, evidence has come to light suggesting that opioids might be undesirable in cancer management.
A number of retrospective clinical studies have demonstrated a lower incidence of cancer recurrence after regional anaesthesia and reduced use of opioids after surgery [2–4]. Laboratory-based studies have reported large amounts of conflicting evidence regarding morphine influence on cell proliferation, apoptosis, invasion/migration and angiogenesis.
The anti-proliferative effects of morphine on cancer cells have been demonstrated in various cell lines including MCF-7 breast cancer cells (due to the activation of opioid receptors) , T47D human breast cancer cells (despite lacking opioid receptors) , PC9 lung cancer cells (due to the inhibition of NF-kB and TNF-α)  and finally in LNCaP, DU145 and PC3 human prostate cancer cells . On the contrary, pro-proliferative effects of morphine have been noted in EL-4 leukaemia cells in mice (although this may have been secondary to immunosuppression) , K562 human leukaemia cells  and HT-29 colon cancer cells (through the increased secretion of the metastasising protein urokinase-type plasminogen activator) .
Similar uncertainty has been shown when looking at morphine effect on cancer cell apoptosis. Anti-apoptotic effects have been demonstrated in SH-SY5Y neuroblastoma cells through a PI3K-signalling cascade . However, using this same cell line, a different study found morphine to induce apoptosis through activation of the mitochondrial death pathway . Pro-apoptotic effects have also been demonstrated in small cell lung cancer cells (due to a reduction in protein kinase C activity)  and Jurkat leukaemia cells .
This study aims to determine the in vitro effects of morphine on bladder cancer cell proliferation and apoptosis. It is hypothesised that morphine, at clinically relevant concentrations, will enhance bladder cancer cell proliferation, possibly due to an inhibitory effect on apoptosis through an opioid receptor-mediated mechanism.
MATERIALS AND METHODS
Reagents. Unless otherwise stated, all reagents were purchased from Sigma-AldrichTM, UK: Morphine sulphate salt pentahydrate; Naloxone methiodide; methylthiazolyldiphenyl-tetrazolium bromide (MTT); RPMI medium; foetal calf serum; 1% L-Glutamine-Penicillin-Streptomycin solution; 0.4% trypan blue; phosphate buffered saline; Dimethyl sulfoxide; Sodium dodecyl sulphate. µ-opioid primary antibody (ab10275) and secondary antibody (ab205718) were from Abcam, UK; CellEvent Caspase-3/7 Green Detection Reagent was from Thermofisher ScientificTM, UK.
Cell culture. RT-112 human urinary bladder transitional carcinoma cells were maintained in RPMI medium supplemented with 10% foetal calf serum and 1% L-Glutamine-Penicillin-Streptomycin solution. The cells were incubated at 37 °C in a humidified atmosphere with 5% CO2 and passaged when they reached 90% confluence.
MTT assay. RT-112 cells (1 • 105) were seeded into the 60 inner wells of 96-well microplates containing 100 µl of culture medium. Phosphate buffered saline was added to the outer 36 wells. Plates were incubated at 37 °C in 5% CO2 for 24 hours. Doubling dilutions of treatment/blocker was then added to the wells (n = 6) except for the eleventh column which was kept as a control. Plates were incubated for a further 72 hours. 50 µl of MTT solution was added to each well. Precipitated formazan crystals were dissolved by adding 100 µl dimethyl sulfoxide. The plates were inserted into the spectrophotometer and read at 570 nm and 630 nm. Each MTT assay was repeated 4 times.
Immunoblotting. RT-112 cells were lysed in breaking buffer (50 mM sodium phosphate, 1 mM PMSF, 1 mM EDTA, 5% glycerol). 10 µg aliquots of protein sample were mixed with 6 × SDS loading buffer, incubated for 10 minutes at 75 °C and loaded on a 4–20% gradient polyacrylamide gel along with the molecular weight marker. The proteins were then transferred onto a nitrocellulose membrane at 30 mA for 2 hours. Following SDS-polyacrylamide gel electrophoresis and electroblotting, membranes were blocked using a 5% milk solution for 2 hours. Following this, they were incubated with the µ-opioid primary antibody (1:1000) and subsequently the secondary antibody for 2 hours each (1:1000). Antibody-labelled protein bands were visualised by enhanced chemiluminescent detection. Coomassie staining was used to exhibit the protein profile of the RT-112 cells.
Apoptosis assay. RT-112 cells (1 • 105) were seeded into a µ-Slide 8-Well Glass Bottom dish. Cells were incubated at 37 °C in 5% CO2 for 24 hours and then treated with morphine/naloxone. The dishes were incubated for a further 72 hours. After removing the media from the cells, CellEvent Caspase-3/7 Green Detection Reagent (Thermofisher ScientificTM, UK) was added to the cells. Cells were imaged using confocal microscopy.
Statistical analysis. MTT assay — results from the plate reader were analysed using Graphpad Prism (Graphpad Software, San Diego, CA). p values were calculated by comparing the control average with an experimental average using Student’s paired t-tests. The 62.5 µM experimental value was deemed the most clinically relevant and therefore was appropriate for statistical analysis to compare against the control [16, 17].
Apoptotic assay — the number of apoptotic cells showing bright green nuclei were calculated as a percentage of the total number of cells and analysed using Graphpad Prism.
Growth response of RT-112 cells to exogenous morphine. Morphine doubling dilutions (250 µM à 0.977 µM) were performed across a 96-well plate. As shown in Fig. 1, the percentage growth of the treated cells was greater than that of the control cells. This effect diminished as morphine concentrations decreased. At the 62.5 µM (clinically relevant) concentration, there was ~7% increase in cell growth (p = 0.0079), whereas at the lowest concentrations of morphine, there was negligible effect.
Fig. 1. Growth response of RT-112 cells to exogenous morphine. Bar chart showing the percentage difference between growth of the treated cells and control cells Statistics is calculated for 62.5 µM compared to control using Student’s paired t-test. **p < 0.05
Growth response of RT-112 cells to morphine after pre-treatment with clinically relevant naloxone dose. A 50 µM blanket dose of naloxone was applied across a 96-well plate, 15 minutes prior to morphine doubling dilutions (250 µM à 0.977 µM). Initially, at the higher doses of morphine, percentage growth was higher than that of the control (Fig. 2). At the 62.5 µM morphine dose, the increase in growth was ~2% which was not significantly different from the control (p = 0.7445) and this was most likely due to the competitive binding of naloxone at the opioid receptors. As morphine concentrations dropped below the 50 µM naloxone dose, percentage growth decreased to below that of the control.
Fig. 2. Growth response of RT-112 cells to morphine after pre-treatment with clinically relevant naloxone dose 50 µM. Bar chart showing the percentage difference between growth of the treated cells and growth of the control cells Statistics is calculated for 62.5 µM compared to control using Student’s paired t-test. ns — non-significant (p > 0.05)
RT-112 cell expression of the µ-opioid receptor. The next step in this study was to determine if the µ-opioid receptor was expressed by RT-112 cells. In dot blot experiments with µ-opioid receptor antibody only a weak signal was obtained. While in Western blot analysis a weak signal corresponded to a molecular weight of 25-30 kDa while the predicted molecular weight of the µ-opioid receptor is 45 kDa (data not shown).
Effect of morphine on RT-112 cell apoptosis. Confocal imaging was used to determine whether morphine, with and without naloxone, had any effect on RT-112 cell apoptosis. Fig. 3, a displays the most representative image of each well in the 8-well glass dish and the treatment that each well received. Note that many images were taken across each well, all of which were analysed during cell counting. Fig. 3, b quantifies the findings from these images. The percentage of apoptotic cells was ~13% in the morphine (50 µM) group ([p = 0.1345), ~28% in the morphine (50 µM) + naloxone (100 µM) group (p = 0.6594) and ~24% in the control group. Despite not achieving statistical significance, these results remain interesting and informative and perhaps shed some light on how morphine exerts its growth-inducing effects.
Fig. 3. The effect of morphine on RT-112 cell apoptosis. a — Confocal images showing the number of apoptotic cells in each well (fluorescent green). M — morphine-treated well; M + N — morphine- and naloxone-treated well; C — control well. b — Bar chart showing the percentage of apoptotic cells in the different treatment groups
This study adds further evidence to the debate that morphine may be undesirable in the management of pain, in patients with bladder cancer (transitional cell carcinoma). Fig. 1 shows that clinically relevant doses of morphine cause RT-112 cell proliferation, corresponding to 5–10% growth increase. Other studies have found comparable results, for example, with human glioma T98G cells  and human colon cancer HCT116 cells (believed to be caused by modulation of cell proliferation and/or apoptosis) . In these studies the concentrations of morphine used were below 1 µM, however, evidence suggests that in peri-operative patients receiving morphine, plasma concentrations can reach higher than 70 µM . This is why 62.5 µM was deemed a clinically relevant concentration in these experiments.
When morphine and naloxone were co-administered, they demonstrated a competitive relationship. Fig. 2 shows that when morphine concentration exceeded naloxone concentration, the result was RT-112 cell proliferation. However, when naloxone concentration exceeded morphine concentration, cell growth was reduced. Percentage growth ranged from +10% to –15% across the plate. This suggests that the growth-enhancing effects of morphine are opioid receptor-mediated.
Involvement of the µ-opioid receptor in regulating cancer progression has been reported in several laboratory studies [20–22]. To determine whether RT-112 cells express µ-opioid receptors, several immunoblotting experiments were performed. Nevertheless, Western blot analysis regarding µ-opioid receptor expression in RT-112 cells in our study remained inconclusive. Finally, in our experiments morphine reduces the rate of apoptosis in RT-112 cells, which may partly explain how morphine causes RT-112 cell proliferation. Naloxone inhibited morphine anti-apoptotic effect. Lin et al. reported similar findings where morphine inhibited doxorubicin-induced neuroblastoma cell apoptosis by the inhibition of reactive oxygen species generation, mitochondrial cytochrome c release and NF-kB transcriptional activation . Morphine has also been shown to protect lymphocytic cells from apoptotic lysis, mediated by opioid receptors .
In our study, morphine, at clinically relevant doses, caused RT-112 bladder cancer cell proliferation. The results support an opioid receptor mediated effect and at least some of this might be due to decreased apoptosis. This has not been reported previously for a bladder cancer cell line but concurs with other studies carried out on different cancer cell lines. Clinically, the use of morphine to manage pain in patients with bladder cancer may need to be carefully considered.
The study was funded by the University of Southampton.
The authors thank members of staff in the Departments of Urology and Clinical and Experimental Sciences at University Hospital Southampton NHS Foundation Trust for their support.
No Comments » Add comments